Barclays Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price

Oruka Therapeutics (NASDAQ:ORKA) had its price target boosted by Barclays from $50.00 to $78.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other research firms also recently issued reports on ORKA. Wedbush reissued an “outperform” rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 13th. Stifel Nicolaus boosted their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Guggenheim reiterated a “buy” rating and issued a $60.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Finally, BTIG Research reiterated a “buy” rating and issued a $73.00 price objective on shares of Oruka Therapeutics in a report on Friday, March 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $64.90.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $60.60 on Tuesday. The company’s 50 day simple moving average is $37.92 and its 200-day simple moving average is $31.34. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -32.58 and a beta of -0.54. Oruka Therapeutics has a 1 year low of $5.49 and a 1 year high of $60.68.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. Equities analysts expect that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the sale, the insider directly owned 33,377 shares of the company’s stock, valued at $1,365,453.07. This represents a 18.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 23,765 shares of company stock worth $849,575. 24.69% of the stock is owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Royal Bank of Canada increased its holdings in Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Oruka Therapeutics during the 4th quarter worth about $37,000. PNC Financial Services Group Inc. purchased a new stake in Oruka Therapeutics during the 3rd quarter worth about $39,000. Caitong International Asset Management Co. Ltd purchased a new stake in Oruka Therapeutics during the 4th quarter worth about $67,000. Finally, Russell Investments Group Ltd. purchased a new stake in Oruka Therapeutics during the 3rd quarter worth about $43,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.